Nektar Therapeutics (NASDAQ:NKTR)
| 0.4938 Delayed Data As of Nov 30 |  +0.0278 / +5.97%Today’s Change | 0.41 Today|||52-Week Range 3.19 | -78.15% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | -81.2M | -153.5M | -96.7M | 681.3M | |
| Depreciation | 12.9M | 15.4M | 14.7M | 10.9M | ||
| Total Other Cash Flow | 29.9M | 13.2M | 39.2M | 65.0M | ||
| Funds From Operations | -38.4M | -125.0M | -42.8M | 757.2M | ||
| Funds From/For Other Operating Expenses | 34.7M | -7.9M | 37.6M | 39.0M | ||
| Net Cash Flow - Operating Activities | -73.1M | -117.0M | -80.4M | 718.2M | ||
| Investing | Increase In Investments | -297.6M | -334.7M | -404.4M | -2.3B | |
| Decrease In Investments | 269.5M | 258.7M | 385.3M | 902.9M | ||
| Capital Expenditures | -11.2M | -6.4M | -9.7M | -14.2M | ||
| Fixed Asset Disposal | -- | -- | -- | 2.6M | ||
| Net Cash Flow Investing | -39.3M | -82.4M | -28.8M | -1.4B | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 241.3M | 0.00 | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -142.7M | -5.9M | -5.1M | 0.00 | ||
| Net Proceeds Stock Sale | 32.2M | 209.6M | 59.5M | 852.0M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Cash Flow - Financing | 130.8M | 203.6M | 54.4M | 852.0M | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -159.0K | -124.0K | -46.0K | -101.0K | |
| Net Change In Cash | 18.4M | 4.2M | -54.8M | 190.2M | ||
